Skip to main content
Premium Trial:

Request an Annual Quote

Genomics Collaborative Close to Announcing Genotyping Partnership

NEW YORK, Oct. 10 - Look out for Genomics Collaborative to strike a genotyping partnership with a prominent SNP company.

 

Michael Pellini, CEO of GCI, said the deal, which he said will be with "a larger genotyping company," is slated to close over the next three months. In it, the SNP company will use parts of GCI's Global repository of tissue, sera, and DNA samples.

 

Speaking to investors at the UBS Warburg global life-sciences conference here today, Pellini explained that this partner, which he declined to name, sought this collaboration because "most of these companies do not have enough samples" to perform the kind of research they'd like.

 

Before bolting out of the room to catch a flight, Pellini said GCI has around $7 million in the bank and will burn approximately $3 million of that next year. He added that he expects the firm to become cash-flow positive in 12 to 15 months.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.